Avidity Biosciences (RNA) News Today $8.23 -0.09 (-1.08%) As of 12:14 PM Eastern Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Avidity Biosciences Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 SyndromeOctober 27 at 6:30 AM | prnewswire.comAvidity Biosciences (NASDAQ:RNA) Stock Picked Up by Analysts at Roth CapitalOctober 24, 2026 | americanbankingnews.comAvidity Biosciences (NASDAQ:RNA) Stock Rated Buy in New Coverage at Roth CapitalOctober 22, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Stock Breaks Below 200 Day Moving Average - Here's WhyOctober 22, 2026 | marketbeat.comAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)October 20, 2026 | prnewswire.comYakira Capital Management Calls on Atrium Therapeutics to Launch Strategic Review, Curb Cash Spending and Explain Dilutive FinancingOctober 20, 2026 | prnewswire.comAvidity Biosciences, Inc. (RNA) - What Are Investment Firms Thinking About This Stock?October 19, 2026 | americanbankingnews.comAvidity Biosciences, Inc. (RNA) - What Are Researchers Thinking About This Stock?October 14, 2026 | marketbeat.comAtrium Therapeutics Announces $50 Million Private PlacementOctober 8, 2026 | prnewswire.comAvidity Biosciences (NASDAQ:RNA) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?October 7, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Shares Cross Below Two Hundred Day Moving Average - Here's What HappenedSeptember 29, 2026 | marketbeat.comAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)September 21, 2026 | prnewswire.comNovartis RNA drug falls short in rare muscle disease studySeptember 9, 2026 | finance.yahoo.comAtrium Therapeutics to Participate in Upcoming Investor ConferencesSeptember 2, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 20, 2026 | prnewswire.comAtrium Therapeutics Reports Second Quarter 2026 Financial ResultsAugust 13, 2026 | prnewswire.comAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationAugust 13, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)July 20, 2026 | prnewswire.comAtrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 SyndromeJuly 14, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)June 23, 2026 | prnewswire.comNovartis Trial Wins Highlight Rhapsido And RNA FSHD Potential For GrowthJune 14, 2026 | finance.yahoo.comAtrium Therapeutics Reports First Quarter 2026 Financial ResultsMay 14, 2026 | prnewswire.comAtrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular CollaborationApril 23, 2026 | prnewswire.comAtrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 20, 2026 | prnewswire.comNovartis Uses US Bond Issue To Expand RNA And Peptide PipelineMarch 19, 2026 | uk.finance.yahoo.comNovartis acquisition spin-off pioneers RNA therapeutics for the heartMarch 19, 2026 | finance.yahoo.comAvidity Biosciences Completes Merger and Plans Nasdaq DelistingMarch 4, 2026 | theglobeandmail.comAtrium Therapeutics Launches with Approximately $270 Million to Advance Novel RNA Medicines for Rare Genetic CardiomyopathiesFebruary 27, 2026 | prnewswire.comAvidity Biosciences Announces Multiple Upcoming Presentations at 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific ConferenceFebruary 26, 2026 | prnewswire.comAvidity Biosciences, Inc.: Avidity Biosciences Announces Expected Record Date for Spin-OffFebruary 26, 2026 | finanznachrichten.deAvidity Biosciences, Inc.: Avidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersFebruary 24, 2026 | finanznachrichten.deAvidity Biosciences Announces Intention to Adjourn and Reconvene Special Meeting of StockholdersFebruary 23, 2026 | prnewswire.comThe New England Journal of Medicine Publishes Results from Phase 1/2 MARINA® Trial of Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1February 18, 2026 | prnewswire.comAvidity Biosciences Announces Expected Record Date for Spin-OffFebruary 2, 2026 | prnewswire.comCiti Remains a Hold on Avidity Biosciences (RNA)January 31, 2026 | theglobeandmail.comAvidity Biosciences (NASDAQ:RNA) Director Sells $127,367.10 in StockJanuary 24, 2026 | insidertrades.comAvidity Biosciences (NASDAQ:RNA) Director Sells $127,367.10 in StockJanuary 23, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 2,929 SharesJanuary 23, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) CFO Sells $329,067.90 in StockJanuary 23, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Sells $354,642.75 in StockJanuary 23, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Sells $473,388.30 in StockJanuary 23, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) CEO Sells $1,042,338.15 in StockJanuary 23, 2026 | marketbeat.comAvidity Biosciences (NASDAQ:RNA) Insider Teresa Mccarthy Sells 1,965 SharesJanuary 10, 2026 | insidertrades.comAvidity Biosciences receives FTC clearance for Novartis mergerDecember 18, 2025 | msn.comTop 2 Health Care Stocks That May Keep You Up At Night In DecemberDecember 16, 2025 | benzinga.comAssessing Avidity Biosciences (RNA) Valuation After a 130% Year-to-Date Share Price SurgeDecember 11, 2025 | finance.yahoo.comDyne upgraded at Oppenheimer on upcoming trial readout from AvidityDecember 10, 2025 | msn.comAvidity Biosciences, Inc. (RNA): A Bull Case TheoryDecember 5, 2025 | finance.yahoo.comAvidity Biosciences, Inc. (RNA): A bull case theoryDecember 4, 2025 | msn.comHalper Sadeh LLC Encourages RNA, TCBX, ATXS, FSUN Shareholders to Contact the Firm to Discuss Their RightsDecember 1, 2025 | prnewswire.com Avidity Biosciences Media Mentions By Week Avidity Biosciences Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RNA News Sentiment▼0.380.69▲Average Healthcare News Sentiment Avidity Biosciences News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RNA Articles This Week▼63▲RNA Articles Average Week Avidity Biosciences Trends on MarketBeatThis week vs. last weekNew Followers1Searches1Page Views2,274+11% Get Avidity Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for RNA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Silence Therapeutics News Today Puma Biotechnology News Today Sagimet Biosciences News Today CytomX Therapeutics News Today Sensei Biotherapeutics News Today Entera Bio News Today Neurogene News Today Monopar Therapeutics News Today Aclaris Therapeutics News Today REGENXBIO News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Avidity Biosciences dated 10/27/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredElon Musk about to bankrupt Amazon, Microsoft & Google?Jeff Brown, the former tech executive who called the rise of Bitcoin, Tesla, and Nvidia years early, is tracki...Brownstone Research | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredThe chip inside every TeslaEvery Tesla built since 2012 pays this small, overlooked supplier a fee for its technology. So does every Star...Behind the Markets | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
